| 26.13 Data as of May 22 |  +0.17 / +0.65%Today’s Change | 13.53 Today|||52-Week Range 27.98 | +16.86% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Medical Specialties | MARKET CAP $376.4M |
Company Description
SurModics, Inc. is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company offers surface modification coating technologies and components for in vitro diagnostic test kits and microarrays. It operates through two segments: Medical Device and In Vitro Diagnostics. The Medical Device segment engages in offering surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device to coronary, peripheral, and neuro-vascular, and urology markets. The In Vitro Diagnostics segment consists of component products and technologies for diagnostic test kits and biomedical research applications. Its products include protein stabilization reagents, substrates, antigens and surface coatings for molecular diagnostic applications. SurModics was founded in June 1979 and is headquartered in Eden Prairie, MN.
Employees
Shareholders
| Mutual fund holders | 43.15% |
| Other institutional | 39.37% |
| Individual stakeholders | 36.39% |
Top Executives
| Gary R. Maharaj, MBA | President, Chief Executive Officer & Director |
| Andrew D. C. LaFrence, CPA | Chief Financial Officer & Vice President |
| Charles W. Olson | Senior Vice President & GM-Medical Device |
| Timothy J. Arens, MBA | Vice President-Corporate Development & Strategy |
| Joseph J. Stich, MBA | VP-Business Operations & GM-In Vitro Diagnostics |
.
